Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo with best supportive care in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.

Yoshino says that TAS-102 is well tolerated overall with very mild toxicity. The most common adverse events observed in the TAS-102 arm were hematologic, including anemia (16.5%) and neutropenia (34.9%).

There were also some incidences of diarrhea, pyrexia and vomiting, Yoshino says, but these were generally manageable. Based on this, Yoshino says he believes that TAS-102 is very well tolerated in almost all patients.

View more from the 2014 World GI Congress

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Colorectal Cancer

 Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

ESMO World Congress on Gastrointestinal Cancer

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo, with best supportive care, in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.

Dr. Yoshino Discusses the Safety Profile of TAS-102